Trump’s FDA Nomination Overlooks Acting Commissioner
Earlier this month, President Donald Trump announced plans to nominate Stephen Hahn as the U.S. Food and Drug Administration (FDA)’s next Commissioner.
Since May 2018, Hahn has been the chief medical executive at the University of Texas MD Anderson Cancer Center (MDACC) in Houston. Since 2015, he’s been MDACC’s Gilbert H. Fletcher Memorial Distinguished Chair and Professor of Radiation Oncology. MDACC is a research-driven patient care organization that has approximately 21,000 employees with an annual revenue of $5 billion and the largest number of clinical trials in the United States.